Navigation Links
Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Date:11/24/2008

PRINCETON, N.J., Nov. 24 /PRNewswire-FirstCall/ --Medarex, Inc. (Nasdaq: MEDX) today announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody for the treatment of cancer. Studies suggest that the PD-1 signaling pathway may play an important role in tumor evasion and escape from host immune responses and may also promote the persistence of certain chronic viral infections.

The Phase 1b clinical trial is designed to primarily evaluate the safety and tolerability of repeated dosing of MDX-1106 in adult patients with solid tumors and will also provide a preliminary assessment of the anti-tumor activity of multiple doses of MDX-1106 (1, 3 or 10 mg/kg) in these patients. The tumors to be studied include malignant melanoma, renal cell cancer, castrate-resistant prostate cancer and non-small cell lung carcinoma. This open label study is expected to enroll up to 76 patients and will be conducted in multiple sites in the United States.

"We believe that anti-PD-1 antibodies could represent the next stage in immunotherapy with a promising mechanism of action and potential for marked synergy with anti-CTLA4 antibodies," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "Preliminary results from our single-dose Phase 1 study demonstrated an acceptable safety profile and initial evidence of anti-tumor activity in cancer. We look forward to the further development of this novel immunotherapy in cancer and, in a separate clinical trial, hepatitis C."

In May 2005, Ono entered into a collaboration agreement with Medarex to research and develop a fully human anti-PD-1 antibody for the treatment of cancer. The two companies plan to share the costs and responsibilities of researc
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...  In anticipation of the upcoming MEDevice San Diego ... the first time. Industry Overview: Medtech & Life Sciences ... snapshot of San Diego,s critical involvement ... latest employment statistics to current venture capital investment trends, the ... such a vital part of the global medical device ...
(Date:8/28/2014)... LONDON , Aug. 28, 2014  A candidate ... The Gambia and Mali ... safety trials of potential vaccines aimed at preventing the disease that ... West Africa . Human trials of ... Health (NIH) and GlaxoSmithKline, are to be accelerated with funding from ...
(Date:8/28/2014)... 2014 According to a new ... (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) - ... 2014 - 2020" the global radiofrequency identification (RFID) market ... is expected to grow at a CAGR of 13.9% ... of USD 5.3 billion in 2020. Browse ...
Breaking Medicine Technology:New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5
... Md., Sept. 15 Pre-mixed insulin,analogues, a modified ... than long-acting analogues for controlling high blood sugar,levels ... according to a report,funded by the Agency for ... of Health and Human Services., Conventional pre-mixed ...
... Results inconclusive, as primary outcome measure not statistically ... by improvement in placebo group, ... -- Overall safety and tolerability profile comparable to placebo, ... -- Next steps include further analysis of full dataset ...
Cached Medicine Technology:Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels 2Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels 3AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease 2AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease 3AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease 4
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 ... of Micro-Needling services in their Latham aesthetic office. ... technology, is one of the first surgeons in the ... . The innovative technique is faster and safer ... , Micro-Needling is a noninvasive procedure , ...
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- Researchers have discovered ... their brains. Dyslexia -- the most commonly diagnosed ... with reading and writing. Previous research showed that ... most of those studies focused only on a small ... functional MRI to analyze how multiple brain regions use ...
(Date:8/29/2014)... August 29, 2014 Parker Waichman LLP, ... to protecting the rights of victims who have been ... (DEA) has announced new regulations for all hydrocodone combination ... (RAPS) report dated August 21, 2014, the DEA ... drugs under federal law. , The long-awaited announcement ...
(Date:8/29/2014)... Hastings and Hastings, a Phoenix personal injury ... many years is pleased to report having saved a ... convenient locations throughout the Valley, Hastings and Hastings offers ... attorney. In addition, experienced personal injury lawyers can arrange ... dedication and service is indicative of a law firm ...
(Date:8/29/2014)... August 29, 2014 Many Americans are ... keep diabetes type 2 at bay, patients should consider ... make the necessary lifestyle changes. While some diabetes risk ... history, advanced age, or belonging to certain ethnic groups, ... – their weight. Carrying extra pounds, especially in the ...
Breaking Medicine News(10 mins):Health News:Williams Revjuva Center Brings Micro-Needling to Latham 2Health News:Scientists Find Differences in Brains of Those With Dyslexia 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 2Health News:The Drug Enforcement Agency (DEA) Just Announced Plans to Regulate All Hydrocodone Combination Drugs as Schedule II Drugs, Parker Waichman LLP Comments 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $20,900 On A Settlement Of $190,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $20,900 On A Settlement Of $190,000 3Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 2Health News:Diet Doc Announces Specialized Diet Plans that Help Patients Prevent Diabetes by Stabilizing Blood Sugar Levels and Losing Excess Fat 3
... Reinberg HealthDay Reporter , TUESDAY, Oct. 5 ... scans for injury-related emergency room visits in the United ... "There has been a dramatic increase in the likelihood ... to emergency departments for injury-related conditions without a corresponding ...
... DATE: Dana-Farber/Children,s Hospital Cancer Care is hosting the 42nd Congress ... pediatric oncology meeting in the world, SIOP is returning to ... Dates:, Thursday, Oct. 21, through Sunday, Oct. 24, ... p.m., Thursday through Saturday, and 8 a.m. to 3 p.m. ...
... Serena Gordon HealthDay Reporter , TUESDAY, Oct. 5 ... they not only protect themselves throughout their pregnancy but may ... few months of life. A study published online ... Medicine found that when women were vaccinated in the ...
... GRAND RAPIDS, MICH., Oct. 5, 2010 Only about ... and vegetable intake recommendations, which means they are ... health benefits (1). Along with vitamins, minerals and fiber, ... carotenoids, which research suggests help support women,s health including ...
... , TUESDAY, Oct. 5 (HealthDay News) -- Sophisticated brain ... patients with mild cognitive impairment are likely to progress ... combination of specialized MRI scans and an artificial intelligence ... were able to predict which patients had mild cognitive ...
... the microscope in a major new study, led by an ... its potential advantages and disadvantages. The study, which is ... examine the motives people have for travelling across national boundaries ... hip or joint replacement, cosmetic surgery and fertility treatment. ...
Cached Medicine News:Health News:MRI, CT Scans for ER Patients Triple Over Decade 2Health News:MRI, CT Scans for ER Patients Triple Over Decade 3Health News:Boston, Oct. 21-24: Largest international pediatric oncology conference 2Health News:Mom's Flu Shot May Protect Baby After Birth 2Health News:Mom's Flu Shot May Protect Baby After Birth 3Health News:Shortfalls in carotenoid intake may impact women's health 2Health News:Shortfalls in carotenoid intake may impact women's health 3Health News:Shortfalls in carotenoid intake may impact women's health 4Health News:Computer-Aided MRI Might Help Predict Alzheimer's 2Health News:Computer-Aided MRI Might Help Predict Alzheimer's 3Health News:Traveling for treatment: The case for and against 2
The Perfecta IMC Stems, manufactured from forged cobalt- chrome, are specifically designed for cemented femoral stem arthroplasty....
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Simple straight stem design for the low-demand patient....
Dual offset femoral stems, hip stems that provide unique and competitive features....
Medicine Products: